Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

Etxeberria I, Bolaños E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sánchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, Ochoa MC, Labiano S, Garasa S, Rodriguez I, Vidal A, Mancheño U, Hervás-Stubbs S, Azpilikueta A, Otano I, Aznar MA, Sanmamed MF, Inogés S, Berraondo P, Teijeira Á, Melero I.

Cancer Cell. 2019 Nov 6. pii: S1535-6108(19)30480-5. doi: 10.1016/j.ccell.2019.10.006. [Epub ahead of print]

PMID:
31761658
2.

Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions.

Abellanas MA, Zamarbide M, Basurco L, Luquin E, Garcia-Granero M, Clavero P, San Martin-Uriz P, Vilas A, Mengual E, Hervas-Stubbs S, Aymerich MS.

J Neuroinflammation. 2019 Nov 22;16(1):233. doi: 10.1186/s12974-019-1628-8.

3.

Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.

Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U, Gorraiz M, Lasarte JJ, Kochan G, Escors D, Sanchez-Paulete AR, Melero I, Prieto J, Hernandez-Alcoceba R, Hervas-Stubbs S, Smerdou C.

Mol Ther. 2019 Nov 6;27(11):1892-1905. doi: 10.1016/j.ymthe.2019.09.016. Epub 2019 Sep 16.

PMID:
31563534
4.

Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.

Vivas I, Iribarren K, Lozano T, Cano D, Lasarte-Cia A, Chocarro S, Gorraiz M, Sarobe P, Hervás-Stubbs S, Bilbao JI, Casares N, Lasarte JJ.

J Vasc Interv Radiol. 2019 Jul;30(7):1098-1105. doi: 10.1016/j.jvir.2019.02.023. Epub 2019 May 14.

PMID:
31101416
5.

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martinez-Ferrandis JI, Bunting KL, Meier S, Sagaert X, Bagnara D, Guruceaga E, Blanco O, Celay J, Martínez-Baztan A, Casares N, Lasarte JJ, MacCarthy T, Melnick A, Martinez-Climent JA, Roa S.

Blood. 2019 May 30;133(22):2401-2412. doi: 10.1182/blood.2018889931. Epub 2019 Apr 11.

PMID:
30975638
6.

Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization.

Carneros D, Santamaría EM, Larequi E, Vélez-Ortiz JM, Reboredo M, Mancheño U, Perugorria MJ, Navas P, Romero-Gómez M, Prieto J, Hervás-Stubbs S, Bustos M.

FASEB J. 2019 Jun;33(6):7578-7587. doi: 10.1096/fj.201801563R. Epub 2019 Mar 20.

PMID:
30892966
7.

The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.

Villanueva L, Silva L, Llopiz D, Ruiz M, Iglesias T, Lozano T, Casares N, Hervas-Stubbs S, Rodríguez MJ, Carrascosa JL, Lasarte JJ, Sarobe P.

Oncoimmunology. 2017 Dec 21;7(4):e1409321. doi: 10.1080/2162402X.2017.1409321. eCollection 2018.

8.

Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice.

Lasarte-Cia A, Lozano T, Pérez-González M, Gorraiz M, Iribarren K, Hervás-Stubbs S, Sarobe P, Rabal O, Cuadrado-Tejedor M, García-Osta A, Casares N, Lasarte JJ.

Front Immunol. 2018 Jan 25;9:68. doi: 10.3389/fimmu.2018.00068. eCollection 2018.

9.

Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.

Lozano T, Gorraiz M, Lasarte-Cía A, Ruiz M, Rabal O, Oyarzabal J, Hervás-Stubbs S, Llopiz D, Sarobe P, Prieto J, Casares N, Lasarte JJ.

Oncotarget. 2017 May 13;8(42):71709-71724. doi: 10.18632/oncotarget.17845. eCollection 2017 Sep 22.

10.

Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, Conde E, Sarobe P, Lasarte JJ, Hervas-Stubbs S.

Cancer Res. 2017 Jul 1;77(13):3672-3684. doi: 10.1158/0008-5472.CAN-17-0236. Epub 2017 May 18.

11.

IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.

Llopiz D, Ruiz M, Infante S, Villanueva L, Silva L, Hervas-Stubbs S, Alignani D, Guruceaga E, Lasarte JJ, Sarobe P.

Oncotarget. 2017 Jan 10;8(2):2659-2671. doi: 10.18632/oncotarget.13736.

12.

In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding.

Rabal O, Pastor F, Villanueva H, Soldevilla MM, Hervas-Stubbs S, Oyarzabal J.

Mol Ther Nucleic Acids. 2016 Oct 18;5(10):e376. doi: 10.1038/mtna.2016.84.

13.

Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine.

Latasa C, Echeverz M, García B, Gil C, García-Ona E, Burgui S, Casares N, Hervás-Stubbs S, Lasarte JJ, Lasa I, Solano C.

PLoS One. 2016 Aug 18;11(8):e0161216. doi: 10.1371/journal.pone.0161216. eCollection 2016.

14.

Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense.

Garaude J, Acín-Pérez R, Martínez-Cano S, Enamorado M, Ugolini M, Nistal-Villán E, Hervás-Stubbs S, Pelegrín P, Sander LE, Enríquez JA, Sancho D.

Nat Immunol. 2016 Sep;17(9):1037-1045. doi: 10.1038/ni.3509. Epub 2016 Jun 27.

15.

Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.

Hervas-Stubbs S, Soldevilla MM, Villanueva H, Mancheño U, Bendandi M, Pastor F.

Oncotarget. 2016 Jan 26;7(4):4522-30. doi: 10.18632/oncotarget.6608.

16.

CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.

Concepcion AR, Salas JT, Sáez E, Sarvide S, Ferrer A, Portu A, Uriarte I, Hervás-Stubbs S, Oude Elferink RP, Prieto J, Medina JF.

Oncotarget. 2015 Oct 6;6(30):28588-606. doi: 10.18632/oncotarget.5665.

17.

Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.

Lozano T, Villanueva L, Durántez M, Gorraiz M, Ruiz M, Belsúe V, Riezu-Boj JI, Hervás-Stubbs S, Oyarzábal J, Bandukwala H, Lourenço AR, Coffer PJ, Sarobe P, Prieto J, Casares N, Lasarte JJ.

J Immunol. 2015 Oct 1;195(7):3180-9. doi: 10.4049/jimmunol.1402997. Epub 2015 Aug 31.

18.

Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.

Unzu C, Melero I, Hervás-Stubbs S, Sampedro A, Mancheño U, Morales-Kastresana A, Serrano-Mendioroz I, de Salamanca RE, Benito A, Fontanellas A.

Gene Ther. 2015 Nov;22(11):856-65. doi: 10.1038/gt.2015.64. Epub 2015 Jul 23.

PMID:
26125605
19.

Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.

Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheño U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC, Sanmamed MF, Thieblemont N, Smerdou C, Hervas-Stubbs S.

Cancer Res. 2015 Feb 1;75(3):497-507. doi: 10.1158/0008-5472.CAN-13-3356. Epub 2014 Dec 19.

20.

Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses.

Dadaglio G, Fayolle C, Zhang X, Ryffel B, Oberkampf M, Felix T, Hervas-Stubbs S, Osicka R, Sebo P, Ladant D, Leclerc C.

J Immunol. 2014 Aug 15;193(4):1787-98. doi: 10.4049/jimmunol.1302974. Epub 2014 Jul 14.

21.

Elucidating sources and roles of granzymes A and B during bacterial infection and sepsis.

Arias MA, Jiménez de Bagües MP, Aguiló N, Menao S, Hervás-Stubbs S, de Martino A, Alcaraz A, Simon MM, Froelich CJ, Pardo J.

Cell Rep. 2014 Jul 24;8(2):420-9. doi: 10.1016/j.celrep.2014.06.012. Epub 2014 Jul 10.

22.

Conventional but not plasmacytoid dendritic cells foster the systemic virus-induced type I IFN response needed for efficient CD8 T cell priming.

Hervas-Stubbs S, Riezu-Boj JI, Mancheño U, Rueda P, Lopez L, Alignani D, Rodríguez-García E, Thieblemont N, Leclerc C.

J Immunol. 2014 Aug 1;193(3):1151-61. doi: 10.4049/jimmunol.1301440. Epub 2014 Jun 27.

23.

Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.

Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, Poutou J, Fortes P, Mancheno U, Bunuales M, Olagüe C, Razquin N, Van Rooijen N, Enguita M, Hernandez-Alcoceba R.

Liver Int. 2015 Apr;35(4):1274-89. doi: 10.1111/liv.12571. Epub 2014 May 10.

PMID:
24754307
24.

Anion exchanger 2 is critical for CD8(+) T cells to maintain pHi homeostasis and modulate immune responses.

Concepcion AR, Salas JT, Sarvide S, Sáez E, Ferrer A, López M, Portu A, Banales JM, Hervás-Stubbs S, Oude Elferink RP, Prieto J, Medina JF.

Eur J Immunol. 2014 May;44(5):1341-51. doi: 10.1002/eji.201344218. Epub 2014 Mar 11.

25.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

26.

The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy.

Quetglas JI, Hervas-Stubbs S, Smerdou C.

Oncoimmunology. 2013 Jun 1;2(6):e24499. Epub 2013 Apr 16.

27.

Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses.

Quetglas JI, Rodriguez-Madoz JR, Bezunartea J, Ruiz-Guillen M, Casales E, Medina-Echeverz J, Prieto J, Berraondo P, Hervas-Stubbs S, Smerdou C.

J Immunol. 2013 Mar 15;190(6):2994-3004. doi: 10.4049/jimmunol.1201791. Epub 2013 Feb 11.

28.

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I.

PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21.

29.

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb.

Morales-Kastresana A, Catalán E, Hervás-Stubbs S, Palazón A, Azpilikueta A, Bolaños E, Anel A, Pardo J, Melero I.

J Immunother Cancer. 2013 May 29;1:3. doi: 10.1186/2051-1426-1-3. eCollection 2013.

30.

Interleukin-15 in gene therapy of cancer.

Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I.

Curr Gene Ther. 2013 Feb;13(1):15-30. Review.

PMID:
23157547
31.

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.

Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13.

32.

Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Bunuales M, Garcia-Aragoncillo E, Casado R, Quetglas JI, Hervas-Stubbs S, Bortolanza S, Benavides-Vallve C, Ortiz-de-Solorzano C, Prieto J, Hernandez-Alcoceba R.

Hum Gene Ther. 2012 Dec;23(12):1258-68. doi: 10.1089/hum.2012.043. Epub 2012 Oct 26.

33.

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.

Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I.

J Immunol. 2012 Oct 1;189(7):3299-310. Epub 2012 Aug 27.

34.

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I.

Mol Ther. 2012 Sep;20(9):1664-75. doi: 10.1038/mt.2012.56. Epub 2012 Jun 26.

35.

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.

Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I.

Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19.

36.

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

Unzu C, Hervás-Stubbs S, Sampedro A, Mauleón I, Mancheño U, Alfaro C, de Salamanca RE, Benito A, Beattie SG, Petry H, Prieto J, Melero I, Fontanellas A.

J Transl Med. 2012 Jun 15;10:122. doi: 10.1186/1479-5876-10-122.

37.

Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo.

Martínez de Lizarrondo S, Roncal C, Calvayrac O, Rodríguez C, Varo N, Purroy A, Lorente L, Rodríguez JA, Doeuvre L, Hervás-Stubbs S, Angles-Cano E, Páramo JA, Martínez-González J, Orbe J.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1477-87. doi: 10.1161/ATVBAHA.112.248773. Epub 2012 Apr 5.

PMID:
22492089
38.

Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes.

Alfaro C, Suarez N, Oñate C, Perez-Gracia JL, Martinez-Forero I, Hervas-Stubbs S, Rodriguez I, Perez G, Bolaños E, Palazon A, Sanmamed MF, Morales-Kastresana A, Gonzalez A, Melero I.

PLoS One. 2011;6(12):e29300. doi: 10.1371/journal.pone.0029300. Epub 2011 Dec 20.

39.

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.

Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolaños E, Hervás-Stubbs S, Perez-Calvo J, Benito A, Peñuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I.

J Immunol. 2011 Dec 1;187(11):6130-42. doi: 10.4049/jimmunol.1102209. Epub 2011 Nov 2.

40.

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation.

Alfaro C, Suárez N, Martínez-Forero I, Palazón A, Rouzaut A, Solano S, Feijoo E, Gúrpide A, Bolaños E, Erro L, Dubrot J, Hervás-Stubbs S, Gonzalez A, Perez-Gracia JL, Melero I.

PLoS One. 2011 Mar 14;6(3):e17922. doi: 10.1371/journal.pone.0017922.

41.

International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010.

Ochoa MC, Hervas-Stubbs S, Palazon A, Martinez-Forero I, Berraondo P, Sarobe P, Melcher A, Melero I.

Cancer Immunol Immunother. 2011 May;60(5):753-6. doi: 10.1007/s00262-011-1000-z. Epub 2011 Mar 5. No abstract available.

PMID:
21380561
42.

Direct effects of type I interferons on cells of the immune system.

Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I.

Clin Cancer Res. 2011 May 1;17(9):2619-27. doi: 10.1158/1078-0432.CCR-10-1114. Epub 2011 Mar 3. Review.

43.

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, Ochoa-Callejero L, Martínez A, Luque A, Dinchuk J, Rouzaut A, Jure-Kunkel M, Melero I.

Cancer Res. 2011 Feb 1;71(3):801-11. doi: 10.1158/0008-5472.CAN-10-1733. Epub 2011 Jan 25.

44.

Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells.

Hervas-Stubbs S, Riezu-Boj JI, Gonzalez I, Mancheño U, Dubrot J, Azpilicueta A, Gabari I, Palazon A, Aranguren A, Ruiz J, Prieto J, Larrea E, Melero I.

Eur J Immunol. 2010 Dec;40(12):3389-402. doi: 10.1002/eji.201040664.

45.

Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α.

Rouzaut A, Garasa S, Teijeira A, González I, Martinez-Forero I, Suarez N, Larrea E, Alfaro C, Palazón A, Dubrot J, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2010 Nov;40(11):3054-63. doi: 10.1002/eji.201040523. Epub 2010 Oct 27.

46.

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, Hernandez-Alcoceba R.

Gut. 2011 Mar;60(3):341-9. doi: 10.1136/gut.2010.211722. Epub 2010 Sep 20.

47.

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.

Suarez N, Alfaro C, Dubrot J, Palazon A, Bolaños E, Erro L, Hervas-Stubbs S, Martinez-Forero I, Morales-Kastresana A, Martin-Algarra S, Sangro B, Lecanda F, Perez-Gracia JL, Gonzalez A, Melero I.

Int J Cancer. 2011 Jul 15;129(2):374-86. doi: 10.1002/ijc.25681. Epub 2010 Nov 16.

48.

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

Perez-Gracia JL, Berraondo P, Martinez-Forero I, Alfaro C, Suarez N, Gurpide A, Sangro B, Hervas-Stubbs S, Ochoa C, Melero JA, Melero I.

Immunotherapy. 2009 Sep;1(5):845-53. doi: 10.2217/imt.09.51. Review.

PMID:
20636027
49.

Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.

Dubrot J, Portero A, Orive G, Hernández RM, Palazón A, Rouzaut A, Perez-Gracia JL, Hervás-Stubbs S, Pedraz JL, Melero I.

Cancer Immunol Immunother. 2010 Nov;59(11):1621-31. doi: 10.1007/s00262-010-0888-z. Epub 2010 Jul 6.

50.

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.

Dubrot J, Milheiro F, Alfaro C, Palazón A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervás-Stubbs S, Prieto J, Jure-Kunkel M, Chen L, Melero I.

Cancer Immunol Immunother. 2010 Aug;59(8):1223-33. doi: 10.1007/s00262-010-0846-9. Epub 2010 Mar 25.

PMID:
20336294

Supplemental Content

Loading ...
Support Center